Search
rGLP-1
go.drugbank.com/drugs/DB05433ExperimentalGLP-1 is a naturally occurring hormone produced in the intestines in response to food intake. … rGLP-1 is a continuous infusion of glucagon-like peptide 1, or GLP-1, targeted for the treatment of congestive heart failure (CHF) in patients ineligible for transplant.
XL765
go.drugbank.com/drugs/DB05241InvestigationalXL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR). … It is being developed by Exelixis, Inc.
Pracinostat
go.drugbank.com/drugs/DB05223InvestigationalPracinostat is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors currently in clinical trials, allowing oral dosing. … Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with potential as an oral therapy for a variety of human hematological and solid tumors.
MLN3897
go.drugbank.com/drugs/DB06505ExperimentalMLN3897, a novel CCR1 inhibitor, disrupts osteoclast formation and blocks the interaction between multiple myeloma cells and osteoclasts.
EGEN-001
go.drugbank.com/drugs/DB05953InvestigationalEGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity
Tesevatinib
go.drugbank.com/drugs/DB11973InvestigationalIn addition, tesevatinib inhibits EphB4, an RTK that is highly expressed in many human tumors and plays a role in promoting angiogenesis. … Tesevatinib is a potent inhibitor of multiple RTKs implicated in driving tumor cell proliferation and tumor vascularization (blood vessel formation).
Phenserine
go.drugbank.com/drugs/DB04892InvestigationalIf this is substantiated in an ongoing clinical trial then phenserine may open the door to an entirely new type of treatment for AD. … Axonyx announced on 20 September 2005 that phenserine was ineffective in two curtailed phase 3 trials.
Pirenzepine
go.drugbank.com/drugs/DB00670ApprovedWithdrawnIt promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. … It also potentiates the effect of other antiulcer agents such as cimetidine and ranitidine. It is generally well tolerated by patients.
International brands: PinSuccinobucol
go.drugbank.com/drugs/DB05399InvestigationalAGI-1067, is a novel small molecule with anti-oxidant and anti-inflammatory properties that was discovered by AtheroGenics and designed to treat atherosclerosis of the blood vessels of the heart, or coronary
Iocarmic acid
go.drugbank.com/drugs/DB13755ExperimentalCategories: Compounds used in a research, industrial, or household setting